Drug Trial Radar · NCT04492293
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
Last checked: Nov 19, 2026Latest source record: Feb 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
115
Planned (sponsor's estimate)
Start
May 27, 2020
Primary completion
Dec 31, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multicenter, single arm, open-lable study of ICP-192. The purpose of this study is to evaluate efficacy of ICP-192 in subjects with surgically unresectable or metastatic bladder urothelial cancer.
Conditions
- Bladder Urothelial Cancer
Interventions
ICP-192Drug
ICP-192 is a white, round, uncoated table
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: From the time of first dose until objective disease progression, an average of 6 months
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
The fifth Medical Center of People's Liberation Army General Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Lanzhou University Second Hospital
Lanzhou, Gansu, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China · Recruiting
The First Hospital of JiLin University
Jilin City, Jilin, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
Shandong University Qilu Hospital
Jinan, Shandong, China · Recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.